Navigation Links
ITN type 1 diabetes study identifies subset of patients with strong response to therapy
Date:8/15/2013

WA, Seattle (August 15, 2013) Primary results from a new clinical trial show that patients with type 1 diabetes treated with the monoclonal antibody teplizumab (MacroGenics, Inc.) exhibit greater preservation of C-peptide, a biomarker of islet cell function, compared to controls. Further analyses identified a discrete subset of the treatment group that demonstrated especially robust responses ("responders"), suggesting that these patients could be identified prior to treatment. The trial, entitled "Autoimmunity-Blocking Antibody for Tolerance in Recently Diagnosed Type 1 Diabetes" (AbATE), was conducted by the Immune Tolerance Network (ITN). The results are available online and will be published in the November issue of the journal Diabetes.

The AbATE study, led by Kevan Herold, MD (Yale University), tested teplizumab, which targets the CD3 receptor found on T cells, in patients with new-onset type 1 diabetes. CD3 is required for T-cell activation, which can lead to the destruction of insulin-producing beta cells. A previous ITN study with teplizumab showed that a single course of the drug slowed C-peptide decline in new-onset patients for a year, after which the effects waned. The aim of the AbATE study was to test whether C-peptide preservation could be prolonged by administering two courses of teplizumab, one year apart.

In this open-label, Phase II study, 77 new-onset patients (ages 8 to 30 years old) were randomized to receive either teplizumab or a control. Those in the treatment arm received the scheduled treatment consisting of two 14-day courses of teplizumab, one year apart. Both arms received intensive diabetes care from certified diabetes educators and were followed for two years. The primary endpoint compared C-peptide preservation between the two groups.

After two years, the teplizumab-treated group showed significantly greater preservation of C-peptide (75-percent higher responses compared to the control grou
'/>"/>

Contact: Philip Bernstein, Ph.D.
ITNCommunications@immunetolerance.org
240-235-6132
Immune Tolerance Network
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Diabetes Research Institute develops oxygen-generating biomaterial
2. New study shines light on barriers to diabetes care in NYC Bangladeshi community
3. Commonly used diabetes drug may help to prevent primary liver cancer
4. Approach to diabetes self-management too narrow, study suggests
5. Gut microbiota transplantation may prevent development of diabetes and fatty liver disease
6. From feast to famine: A metabolic switch that may help diabetes treatment
7. Increased fructose consumption may deplete cellular energy in patients with obesity and diabetes
8. Jack Spratt diabetes gene identified
9. Diabetes drug makes brain cells grow
10. Obesity plus low vitamin D may add up to a greater risk of diabetes
11. Joslin researchers gain new understanding of diabetes and kidney disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... and nitrogen comprise all spheres of our planet. ... caused imbalances and perturbations that resulted in increases ... result in climate changes which influence the complex ... atmosphere. Understanding these feedback mechanisms has become an ... during the past three decades. , In parallel, ...
(Date:9/18/2014)... that when people are too stressed they are often ... Brain Mind Institute (BMI) at EPFL have just highlighted ... chronic stress and the loss of social skills and ... a synaptic regulatory molecule in the brain. This was ... . , Carmen Sandi,s team went to look ...
(Date:9/18/2014)... probably the ultimate form of camouflage: you don,t just ... strategy is not as uncommon as you might think. ... USA, explains that the larval life stages of many ... of the anatomy that most creatures cannot make transparent. ... to shield each individual eye unit with an opaque ...
Breaking Biology News(10 mins):Greenhouse gas research enters a new era 2How stress tears us apart 2Transparent larvae hide opaque eyes behind reflections 2
... chronic stress day after day can produce wear and tear ... detrimental effect on learning and emotion. However, acute stress ... memory. Researchers at the University at Buffalo have shown, ... stress can produce a beneficial effect on learning and memory, ...
... and their colleagues have identified the gene that is mutated ... paraganglioma (PGL). The gene, called hSDH5, is required for activation ... the chemical reactions that take place within cells to convert ... in the journal Science , to be released online ...
... , , , ... recent analysis of the automated optical inspection (AOI) equipment market, ... & Sullivan Award for Product Innovation of the Year for ... system combines high-speed inspection with superior performance, accuracy, quality, and ...
Cached Biology News:Short stressful events may improve working memory 2Scientists discover gene mutation responsible for hereditary neuroendocrine tumor 2Scientists discover gene mutation responsible for hereditary neuroendocrine tumor 3Frost & Sullivan Recognizes MIRTEC With the 2009 Award for Automated Optical Inspection Product Innovation of the Year 2Frost & Sullivan Recognizes MIRTEC With the 2009 Award for Automated Optical Inspection Product Innovation of the Year 3
(Date:9/19/2014)... electricity, to move data would consume much less ... concern as chips, transistor counts rise. , Of ... light emitters, modulators, and detectors emitters are ... for optical chips is molybdenum disulfide (MoS2), which ... single, atom-thick layer. Other experimental on-chip light emitters ...
(Date:9/19/2014)... September 19, 2014 Biotech companies ... of emerging drug systems and advanced Laboratory Instrumentation. Companies ... Company (NYSE: BDX ), Thermo Fisher Scientific ... (NASDAQ: RGDO ), Sangamo Biosciences Inc. (NASDAQ: ... Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or ...
(Date:9/19/2014)... September 19, 2014 BioTech News ... patents and results of studies and trials.  Companies in ... Company (NYSE: LLY ), Gilead Sciences Inc. ... CELG ) and Arena Pharmaceuticals Inc. (NASDAQ: ARNA) ... developing prodrug therapeutics for the treatment of cancer, announced ...
(Date:9/19/2014)... 2014 Dublin ... has announced the addition of the  "Micro Market ... their offering.       (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ... the fastest-growing segments in the chromatography market. The ... and expected to reach $2.0 billion by 2019, ...
Breaking Biology Technology:Toward optical chips 2Toward optical chips 3Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 2Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 3Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 4Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 5Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 6Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 7Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 2Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 3Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 4Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 5Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 6Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 7Micro Market Monitor : Global Pre-packed Chromatography Columns 2
... Maxygen, Inc. (Nasdaq: MAXY ) that it has ... also known as R7025.,MAXY-alpha is a novel interferon-alpha for ... and is licensed to Roche. Preliminary observations from ... the pharmacodynamic and pharmacokinetic effects of,MAXY-alpha occurred in the ...
... ITMN ) today announced the pricing of its ... stock at a price to the,public of $19.50 per ... purchase up to an additional 525,000 shares of common,stock. ... sold by InterMune. Goldman, Sachs & Co. is ...
... YORK, Sept. 21 Keryx Biopharmaceuticals,Inc. (Nasdaq: KERX ... to,the Company,s Board of Directors. Mr. Tarnok, 53, ... with extensive pharmaceutical industry experience in a wide,range of ... career at,Pfizer Inc., which he joined in 1989 as ...
Cached Biology Technology:Maxygen Announces Hold on MAXY-alpha Development Program 2Maxygen Announces Hold on MAXY-alpha Development Program 3InterMune Announces Pricing of $68 Million Public Offering of Common Stock 2Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors 2
... The EC570-90 is a compact, lightweight, high ... 500 volts or 2500 milliamps. It is an ... RNA submarine gels. It is also ideal for ... time can be set to automatically end a ...
Rat Hepatocytes (RH) (>3,000,000 cells)...
QCPN...
Rat Aortic Smooth Muscle Cells (RAOSMC) (>500,000 cells)...
Biology Products: